TerminatedPhase 3

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

Stopped: Terminated due to low recruitment.

United States4 participantsStarted 2003-07

Plain-language summary

Objectives: * Determine the corrected count increment of autologous transfused platelets that had been stored by cryopreservation with ThromboSol. * Determine the ability of autologous platelets that had been stored by cryopreservation with ThromboSol to correct thrombocytopenia.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: 1\) 1.- Patients in remission with ALL, CLL, AML, CML, MDS will be allowed to participate in this program if their platelet count is \>150K, and the hemoglobin level is at least 8.0g/dl. The patient will receive their autologous platelets cryopreserved in ThromboSol or the fresh random platelets (FRP) whenever the need for such transfusions is determined to be clinically indicated by their physician(s). Exclusion Criteria: 1\) Patients with detectable circulating malignant cells or ongoing marrow involvement by the tumor will not be eligible.

What they're measuring

Patient Platelet Counts (CCI) Post-transfusion

Timeframe: Baseline and 18-24 hour post-transfusion platelet counts

Trial details

NCT IDNCT00074763

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-01

View on ClinicalTrials.gov More Leukemia trials